Israel-based medical device company developing a breakthrough wearable technology for detecting, monitoring, and non-invasively treating cardiac arrhythmias using drug-free neuromodulation, CardiaCare announced the closure of its seed extension round. The oversubscribed round took place on September 18, 2023. However, the company did not disclose the amount of the funding. Solardis Health Ventures led the financing for the firm.
Purpose of financing for CardiaCare
With the latest proceeds from the seed extension round, the company has plans to expand the technology’s clinical program for multiple indications related to treating Atrial Fibrillation (AFib)
What the company’s officials have to comment
Ofer Halbreich, CEO of the company, said, “The oversubscribed closure of this round is a reflection of the potential of CardiaCare’s technology to disrupt the standard of care for AFib. We are proud to have Solardis Health Ventures, along with savvy clinical and commercial leaders, support our journey. The funds will be used to support existing and future double-blind, multicenter clinical studies to demonstrate the clinical efficacy of CardiaCare’s therapy for various indications.”
In addition, Ken Nelson, Chairman of CardiaCare, said, “CardiaCare’s innovative solution has the potential to significantly disrupt the standard of care in the treatment of AFib and other arrhythmias with a non-invasive wearable that administers neuromodulation stimulation therapy. Multiple clinical studies are already underway as we push to bring this advancement in cardiac care to market.”
What the lead investor for the company has to say
Besides, Amir Soltanianzadeh, Founder & Managing Partner of Solardis Health Ventures, said, “CardiaCare’s novel approach to treating AFib using neuromodulation will be a paradigm shift for the millions of patients that have no alternatives to toxic drugs, cardioversion shock therapy, or invasive procedures. Solardis Health Ventures is proud to lead this round and support CardiaCare’s mission to become the first therapeutic wearable for cardiac arrhythmia patients.”
About the company
Cardiac arrhythmia specialist and entrepreneur Amos Ziv launched the company in 2018. He has an experince of over a decade of caring for and creating new therapies for patients with AFib. CardiaCare is a privately-held, Israel-based company. It is in the process of developing a platform for both treating and monitoring cardiac arrhythmias such as Atrial Fibrillation. CardiaCare’s platform can simultaneously help physicians remotely monitor their patients as well as create dynamic, personalized neuromodulation treatments. The treatments are based on the real-time patient’s condition data.
CardiaCare’s mission is to become the new standard of care, an all-in-one therapeutic monitoring platform for cardiac arrhythmia patients across the continuum of care.
For more extensive analysis and Market Intelligence reports, feel free to approach us.
We try our best to fact-check and bring well-researched as well as non-plagiarized content to you. Please let us know
if there are any discrepancies in any of our published stories,
-how we can improve,
-what stories you would like us to cover
–what information you are looking for in the comments section below or through our contact form! We look forward to your feedback, and thank you for stopping by!
Next Article
